Good News for TNBC MBC Patients!

Bestbird

If your cancer is Triple Negative (TNBC) and you've already had two or more therapies for metastatic disease, then you're eligible to receive the newly-approved drug Trodelvy (Sacituzumab Govitecan – formerly IMMU-132).

Trodelvy, which is administered intravenously, consists of the chemotherapy drug irinotecan linked with an antibody targeted against TROP-2, a cell-surface protein that is expressed in more than 90% of TNBC.FDA approval was based upon a Phase 1/2 trial of 108 TNBC MBC patients who had previously undergone a median of three prior lines of therapy (80% of whom had visceral metastases).The results of the study determined that the median Progression-Free Survival (PFS) was 5.5 months and the median Overall Survival (OS) was 13.0 months. From: https://www.oncnursingnews.com/web-exclusives/fda-approves-sacituzumab-govitecan-for-triplenegative-breast-cancer

The above and similar information about approved MBC treatments and cutting edge research is in my book, "The Insider's Guide to Metastatic Breast Cancer" which is also available as a complimentary .pdf.For information, please visit https://www.insidersguidembc.com/about